Israel to expand use of COVID drug that gets 88% of patients out of hospital

The drug, MesenCure, has been tested by Rambam Medical Center as part of a Phase I/II trial. The ministry has approved allowing any interested Israeli hospital to take part in the Phase II trial and to use the drug for additional approved patients.
The goal of the expanded trial, which will include a minimum of 50 patients, is to confirm the safety and efficacy of the drug, which was developed by Bonus BioGroup. [ Source: Jerusalem Post (Read More…) ]
Worthy News reports from a biblical worldview with a commitment to accuracy, transparency, and editorial independence. Learn more about About Worthy News, our Editorial Standards, AI Use Policy, Ownership of Worthy News, News Tips and Corrections, and Worthy News Staff.
đĄ Did you know? One of the best ways you can support Worthy News is by simply leaving a comment and sharing this article.
đ˘ Social media algorithms push content further when thereâs more engagement â so every đ like, đŹ comment, and đ share helps more people discover the truth. đ
